Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemotherapy, in the First-line Treatment of Participants with Metastatic Non-Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2022
This article has no abstract
Epistemonikos ID: 01196f71aa9732f1544371e821c19cf14a0bcd85
First added on: Mar 21, 2025